文献速递神经肌肉病

长期静脉给予依达拉奉治疗肌萎缩侧索硬化患者的安全性与有效性

Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项多中心倾向评分匹配队列研究在德国12家ALS转诊中心纳入324例患者,比较静脉依达拉奉联合利鲁唑与单用利鲁唑的疗效。依达拉奉组与标准治疗组的ALSFRS-R下降速率无显著差异,长期治疗可行且主要耐受良好,但未显示疾病修饰获益。

要点

  • 静脉依达拉奉组与标准治疗组的ALSFRS-R下降速率无显著差异(P=0.37)。
  • 潜在不良反应见于30例(16%),最常见为输注部位感染和过敏反应。
  • 在符合MCI186-ALS19纳入标准亚组中,依达拉奉与匹配患者结局亦无差异。

核心结论

  • 长期静脉依达拉奉治疗ALS可行且主要耐受良好,但未显示疾病修饰获益,与单用标准治疗相比可能不提供有临床意义的额外获益。

研究设计与样本

  • 多中心倾向评分匹配队列研究,2017年6月至2020年3月在德国运动神经元病网络下属12家学术性ALS转诊中心开展。
  • 筛查1440例患者,738例纳入倾向评分匹配,最终分析纳入324例ALS患者,包括194例开始静脉依达拉奉治疗者(141例接受≥4个连续治疗周期,其中130例匹配)和130例倾向评分匹配的接受标准治疗的ALS患者。
  • 所有患者均符合El Escorial标准很可能或确诊ALS,发病时间在2012年12月至2019年4月之间。
  • 按MCI186-ALS19研究纳入标准定义亚组,评估患者是否符合(EFAS)或不符合(non-EFAS)该研究标准。

主要发现

  • 194例开始静脉依达拉奉治疗的患者中,125例(64%)为男性,中位年龄57.5岁(IQR 50.7-63.8岁)。
  • 潜在不良反应见于30例(16%),最显著为输注部位感染和过敏反应。
  • 116例接受依达拉奉治疗(中位13.9个月,IQR 8.9-13.9个月)与116例接受标准治疗(中位11.2个月,IQR 6.4-20.0个月)的患者疾病进展无差异:ALSFRS-R评分下降为每月-0.91分(95%CI -0.69至-1.07)vs 每月-0.85分(95%CI -0.66至-0.99),P=0.37。
  • 次要终点生存概率、至通气时间及治疗前后疾病进展变化均无显著差异;在EFAS和非EFAS亚组中,依达拉奉治疗与匹配患者结局亦无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in which efficacy was expected. OBJECTIVE: To evaluate the long-term safety and effectiveness of intravenous edaravone therapy for patients with ALS in a real-world clinical setting. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, propensity score-matched cohort study conducted between June 2017 and March 2020 at 12 academic ALS referral centers associated with the German Motor Neuron Disease Network. Of 1440 patients screened, 738 were included in propensity score matching. Final analyses included 324 patients with ALS comprising 194 patients who started intravenous edaravone treatment (141 received ≥4 consecutive treatment cycles; 130 matched) and 130 propensity score-matched patients with ALS receiving standard therapy. All patients had probable or definite ALS according to the El Escorial criteria, with disease onset between December 2012 and April 2019. Subgroups were defined by applying the MCI186-ALS19 study inclusion criteria to evaluate whether patients would have been considered eligible (EFAS) or ineligible (non-EFAS). EXPOSURES: Intravenous edaravone plus riluzole vs riluzole only. MAIN OUTCOMES AND MEASURES: Patient characteristics and systematic safety assessment for patients who received at least 1 dose of intravenous edaravone. Effectiveness assessment of edaravone was conducted among patients who received at least 4 treatment cycles compared with propensity score-matched patients with ALS who received only standard therapy. Primary outcome was disease progression measured by decrease in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Secondary outcomes were survival probability, time to ventilation, and change in disease progression before vs during treatment. To account for the matched design, patients receiving edaravone and their corresponding matched controls were regarded as related samples in disease progression analyses; stratification for propensity score quintiles was used for survival probability and time to ventilation analyses. RESULTS: A total of 194 patients started intravenous edaravone treatment; 125 (64%) were male, and the median age was 57.5 years (IQR, 50.7-63.8 years). Potential adverse effects were observed in 30 cases (16%), most notably infections at infusion sites and allergic reactions. Disease progression among 116 patients treated for a median of 13.9 months (IQR, 8.9-13.9 months) with edaravone did not differ from 116 patients treated for a median of 11.2 months (IQR, 6.4-20.0 months) with standard therapy (ALSFRS-R points/month, -0.91 [95% CI, -0.69 to -1.07] vs -0.85 [95% CI, -0.66 to -0.99]; P = .37). No significant differences were observed in the secondary end points of survival probability, time to ventilation, and change in disease progression. Similarly, outcomes between patients treated with edaravone and matched patients did not differ within the EFAS and non-EFAS subgroups. CONCLUSIONS AND RELEVANCE: This cohort study using propensity score matching found that, although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit. Intravenous edaravone may not provide a clinically relevant additional benefit compared with standard therapy alone.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Witzel S, Maier A, Steinbach R, et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2022. PMID: 35006266. doi:10.1001/jamaneurol.2021.4893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。